NCT02249091 - A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions

Acute Myeloid Leukemia (Relapsed/Refractory)

Interventions

DRUG

Selinexor

Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m\^2 or 6 doses of 60 mg per induction cycle).

DRUG

Idarubicin

Infusion, iv, 10 mg/m\^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2

DRUG

Cytarabine

Continuous infusion day 1 to 7, 100 mg/m\^2, iv,

Trial Locations (3)

Universitätsklinikum Hamburg-Eppendorf, Hamburg

Medizinische Hochschule Hannover, Hanover

Universitätsklinikum Frankfurt, Frankfurt am Main